Install
Tune in Weekday Mornings Join the Fun with Community Events & Concerts! Clay Travis and Buck Sexton Show The Pizza Battle is back Sioux Falls! Stampede $5 Tickets ↪ How to Listen: Apps & Smart Speakers Advertise with KELO-AM ↪ Markley, Vancamp & Robbins Get our VIP Club Emails Become a Mobile Insider!
- 1,130articles · 30d
- 2+ hour agolatest article
- Aug 15, 2026earliest in window
- 1%with images
- 313avg words
- business 467
- world 295
- world news 270
- politics 260
- (midwest communications 258
- sports 224
- markets 211
- conservative talk 201
- donald trump 198
- brian kilmeade 187
- mc complete - state & national 182
- clay travis 171
- buck sexton 166
- sean hannity 160
- mark levin 145
- joe pags 136
- technology 129
- finance 123
- ben shapiro 121
- economy 104
- Economy, Business & Finance 427
- News 421
- Finance & Business 345
- Politics 271
- Sports & Fitness 215
- Sports 213
- Sport 194
- Politics2 161
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
1+ week, 6+ day ago (303+ words) Aug 31 (Reuters) – Eli Lilly said on Monday it would acquire privately held Merida Biosciences for up to $2.88 billion in cash, strengthening its immunology portfolio with an experimental treatment for thyroid-related autoimmune conditions. Lilly has been on an acquisition spree following…...
McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
2+ week, 5+ day ago (311+ words) By Sahil Pandey and Siddhi Mahatole Aug 25 (Reuters) – McKesson said on Tuesday it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion, as part of a years-long effort to strengthen its higher-growth businesses. The U....
Explainer-How the Merck/Moderna cancer vaccine works and possible barriers to wide use
2+ week, 5+ day ago (579+ words) By Mariam Sunny and Christy Santhosh Aug 25 (Reuters) – The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited. Interim…...
Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results
3+ week, 4+ day ago (382+ words) Aug 19 (Reuters) – Moderna’s personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread when used in combination with the U.S. drugmaker’s blockbuster treatment Keytruda in a late-stage trial. The interim results showed statistically significant…...
Moderna shares surge as Merck-partnered melanoma vaccine cuts recurrence in large trial
3+ week, 4+ day ago (552+ words) By Julie Steenhuysen and Michael Erman CHICAGO, Aug 19 (Reuters) – Moderna’s personalized mRNA cancer therapy, developed with Merck, reduced the risk of recurrence and spread of skin cancer in a late-stage trial when combined with immunotherapy drug Keytruda, sending Moderna’s shares…...